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Introduction
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The possible interaction between exogenous reproductive hormones and athletic performance in females is an important issue that has been the topic of debate for at least four decades 1 . ere are numerous review articles on the e ect of oral contraceptives (OC) on athletic performance [2] [3] [4] [5] [6] , however we feel that these reviews are insu cient as they do not include all categories of hormonal contraceptives. In addition to OCs, there are many other delivery systems for hormonal contraceptives including Intrauterine Devices (IUDs), injections, transdermal patches, implants and vaginal rings. TABLE 1 shows the characteristics of each type of hormonal contraceptive.
Most hormonal contraceptives contain the synthetic oestrogen Ethinyl Estradiol (EE), however there are four generations of progestins, each with varying androgenicity and potency; for a comprehensive review see B et al. 7 . Each type of hormonal contraceptive has multiple formulations and brands that supply oestrogens and/or progestins in various concentrations for di erent durations 8 . As such, the term "hormonal contraceptives" is an umbrella phrase that refers to any type of exogenous hormones that alters endogenous endocrine function and prevents pregnancy 8 . is is the rst paper to consider the e ects of a large variety of hormonal contraceptives on athletic performance, as opposed to focussing on OCs as previous reviews have.
Recent data suggest that ~22% of the general population uses OCs, with ~9% using other forms of hormonal contraceptives 9 . In athletes, the prevalence of OC use is estimated to be 40-50%
Since this time, the use of long-acting contraceptive methods, such as the IUD and implant, has been increasing 12 and therefore we suggest that it is important to understand not only how OCs in uence performance, but also how other methods
Do hormonal contraceptives affect body composition?
of hormonal contraceptives may affect female athletes. is article will present a brief overview of the effects of different types of hormonal contraceptives on a number of factors that in uence athletic performance. Body composition is an important determinant of athletic performance; excess fat mass can impair performance by negatively a ecting the powerto-weight ratio 13 , reducing speed and agility 14 , limiting the availability of lean mass in weight category sports 13 and hindering aesthetic sports 15 . Hormonal contraceptives are widely purported to induce weight gain by athletes 16 and the general population 17 although systematic reviews of combined contraceptives 18 and progestinonly contraceptives 17 have reported inconsistent ndings. In the general population, several studies have shown that the Depot Medroxyprogesterone Acetate (DMPA) injection increases fat mass when compared to combined OC use [19] [20] and nonhormone controls 19, 21 . Levonorgestrel IUD use resulted in a 2.5% increase in fat mass after 12 months usage, compared to a non-hormonal copper based (TCu380A) IUD group who lost 1.3% fat mass 22 and Levonorgestrel implant (Norplant) use resulted in signi cant increases in body mass when compared to non-hormone groups after 6 23 and 12 months 24 . e use of an etonogestrel implant (Implanon) has also resulted in body mass increases of 3% over 2 years 25 . is evidence suggests that progestin-only contraceptives may result in greater increases in body mass than combined contraceptives in the general population, although these data may not be applicable to athletes as they exercise frequently and monitor their dietary energy intake closely 15 .
In a prospective randomised-controlled study, P -G et al. 16 demonstrated that athletes e ability to accrue muscle mass in response to training is bene cial as lean body mass is related to performance indices such as strength, speed and endurance [31] [32] . The regulation of muscle anabolism and catabolism is affected by many factors and exogenous oestrogens and progestins may directly in uence this process or indirectly influence hypertrophic adaptations by altering the concentrations of anabolic hormones 33 . In the general population, progestin only-contraceptives appear to have a negative effect on lean mass. B et al. 20 reported that women who received the DMPA injection lost 3.6% lean mass over 2 years compared to a DMPA and oestradiol group (-1.2%), OC group (+0.6%) or control group with no hormones (+0.6%). Women using a Levonorgestrel IUD lost 1.4% of their lean mass after 1 year compared to a 1.0% increase in lean mass in women using a copper-based (Tcu380A) IUD 22 and combined OCs have also been observed to have a negative e ect on lean mass compared to control populations 19 . In athletes, P -G et al. 16 demonstrated that regularly menstruating runners assigned to a second generation OC (30 µg EE and 0.3 mg Norgestrel) for 2 years accrued a greater amount of
Is there a relationship between hormonal contraceptives and muscle mass?
who were given a combined OC (Norgestrel; n = 69) lost more body and fat mass and gained more lean mass than a control group (n = 81) not using hormonal contraception. Conversely, R et al. 26 found that 10 months OC (Levonorgestrel) use increased body mass (4.3%) and fat mass (17.3%) in oligomenorrheic participants (n = 13) but did not signi cantly a ect eumenorrheic participants body composition (n = 13), despite mean increases of 3.0% and 3.8% for body and fat mass. R et al. 26 used a relatively small sample size and in the absence of a power calculation it may be that the sample size was not su cient to detect signi cant changes in body composition. is highlights the need for further research before the relationship between hormonal contraceptive use and body composition is fully understood in athletes.
Although data are inconclusive for contraceptive use and weight-gain, mechanisms have been identi ed which support a role for both combined and progestin-only contraceptives increasing body mass. Synthetic progestins have been hypothesised to act in a glucocorticoid-like manner, which results in increased appetite and visceral fat deposition [27] [28] [29] [30] . Androgenic contraceptives may also interfere with appetite regulation by suppressing the secretion of the satiating hormone cholecystokinin 25 . It is unclear whether the addition of oestrogens in combined contraceptives in uences the e ects of the progestins 26 . However, in both combined and progestin-only contraceptives there is a down-regulation of reproductive hormones which has been demonstrated to reduce basal metabolic rate [27] [28] , increase visceral fat deposition 29 , increase concentrations of appetite-stimulating hormones 30 and reduce the concentrations of satiating hormones 30 . e combination of these factors suggests that contraceptive use may result in weight gain but this has not been demonstrated in athletes 16, 24 .
lean mass (0.67 kg·year
) than a control group of runners given no hormones(-0.10 kg·year -1 ). e mechanisms behind these changes were not reported and as no indices of performance were measured it is unclear whether these changes resulted in improved performance. To date, only two studies have examined how OC use in uences the response to resistance training [34] [35] . N et al. 34 assessed the response of athletes using various preparations of OCs (n = 13) and athletes not using hormonal contraception (n = 18) to 12 weeks of resistance training. Strength was improved in both groups, with no apparent di erences between groups, although this study did not control for menstrual cycle phase when measuring strength in the control group, which has been shown to a ect force production 36 . In contrast, L et al. 35 found that non-OC users (n = 39) gained signi cantly more muscle mass (+3.5%) than OC users (n = 34; +2.1%) following a 10 week training programme. Further di erences were observed within the OC group, with those taking low androgenicity OCs having a 2.5% increase compared to a 0.3% increase in high androgenicity OC users. It is likely that the di erences in muscle mass shown by L et al. 35 of su cient magnitude to e ect overall athletic performance. e higher androgenicity progestins may have a higher a nity to androgen receptors, which limits the binding of testosterone and thus supresses muscle strength gains 37 . These findings suggests that exogenous hormones may in uence the anabolic response of muscle to resistance exercise. e myo brillar protein fractional synthetic rate (FSR) does not vary across the menstrual cycle 38 , however H et al. 39 demonstrated that females using a third generation OC (30 33, 40 . EE increases the proliferation of satellite cells in rat muscle tissue 41 , indicating that the synthetic component of hormonal contraceptives may have a direct anabolic e ect on muscle, possibly due to a local activation of IGF-1 pathway through an autocrine or paracrine manner 42 .
Hormonal contraceptives may indirectly in uence muscle metabolism by altering the concentrations of anabolic hormones such as testosterone, Growth Hormone (GH) and insulin-like growth factor 1 (IGF-1) 43 . A recent meta-analysis showed that OC use reduced free testosterone by 61% compared to non-users 44 , possibly due to an increase in sex hormone binding globulin concentration, which binds to testosterone rendering it inactive. OC use increases GH concentrations [45] [46] with second (30 µg EE and 0.125 mg Levonorgestrel) and fourth generation (30 µg EE and 2 mg Dienogest) OCs reducing concentrations of IGF-1, but not a ecting IGF binding protein-1 concentrations 45 . e generation of contraceptive in uences the response of IGF-1; 30% reduction following fourth generation OC use compared to 12% reduction following second generation use 46 , possibly as the androgenic Levonorgestrel opposes the e ects of oestrogen on IGF-1 concentrations. In addition, twelve weeks use of a transdermal oestrogen patch (Estraderm) and oral oestrogen (Estrace) has also been shown to increase GH release 47 . It is currently unclear if these di erences in anabolic hormone concentrations with di erent methods of contraception in uence the response to strength training in female athletes.
A cross-sectional study found poorer handgrip force production and endurance in OC users (8 di erent types) than eumenorrheic controls 48 . However, studies comparing pill-taking days and non-pill taking days have generally found no di erence in strength at these time points [49] [50] [51] [52] , although there is some limited evidence that strength is greater on non-pill taking days 53 . L 5 , using a prospective research design, reported no di erence in knee exion and extension strength after 2 months of rst generation OC use. To date, no research has been conducted assessing muscle strength in progestin-only OCs or other methods of hormonal contraception and few studies have been conducted in athletic populations 5, 53 .
How do hormonal contraceptives infl uence muscle strength?
e reduction in free testosterone and oestrogen concentration with contraceptive use 18, 44 may a ect muscle force production as both hormones have a non-genomic action on skeletal muscle, by increasing intracellular calcium concentrations and in uencing the contractile properties of the muscle [54] [55] . Despite this, few studies have shown an e ect of down-regulated reproductive hormones on skeletal muscle force production 56 . Indeed, previous research from our group 57 demonstrated that supra-physiological concentrations of oestrogen and progesterone do not in uence force production in non-trained women.
Is oxygen uptake affected by hormonal contraceptive use?
Many studies have shown that OC use results in a significant reduction in maximal oxygen uptake (VO 2max ) in non-athletic women after 2-6 months use 53, [58] [59] [60] [61] [62] which is reversed when OC use is terminated 58, 60 . is may be due to a reduced activation of the sympathetic nervous system in ovarian suppressed women 63 or a reduction in mitochondrial citrate 58 . However, other more recent studies have found no e ect of OC use on VO 2max in athletes [64] [65] , possibly due to the use of di erent formulations of OC or the training status of the participants.
What are the effects of hormonal contraceptives on performance tests? B et al. 60 detected a 7% reduction in VO 2max with OC use (35 µg EE, 1 mg Norethindrone), although this had no e ect on performance in a treadmill running exercise capacity test. Similarly, J et al. 62 observed a reduced VO 2max in OC users compared to eumenorrheic controls; however there was no di erence in cycling capacity performance. In addition, no di erences were observed in rowing exercise capacity 65 or 200 m swim performance 66 at di erent stages of the OC cycle in well-trained athletes. In a prospective study, R et al. 26 measured endurance capacity, isometric quadriceps strength and handgrip strength in 26 female endurance athletes (13 eumenorrheic and 13 oligo-amenorrheic) before and after 10 months treatment with an OC (30 µg EE and 150 µg Levonorgestrel). ere was no e ect of OC consumption, except a small decrease in exercise capacity in the initially oligo-amenorrheic group, although this may have been due to the inferior response to training observed in ovarian/energy suppressed athletes 67 . Further studies using exercise performance tests are needed, as the majority of past research has examined exercise capacity tests, which are not as ecologically valid as performance tests.
Final considerations
As we have demonstrated in this paper, it is di cult to determine the role of hormonal contraceptives on performance as the majority of studies are cross-sectional and there is a paucity of prospective, randomised-controlled trials. is is especially true for studies using progestin-only contraceptives, which have barely been considered in the general population and have not been studied at all in an athletic population (TABLE 2) . A large number of studies have compared pill-taking days to non-pill taking days, even though data from our laboratory has shown there is no signi cant di erence in hormone pro le between these conditions 68 . Moreover, di erent pill types and formulations are often grouped together making it di cult to discern possible e ects, as the potency and androgenicity of the synthetic hormones may in uence the response 7 and we have previously demonstrated that the hormonal pro le is a ected by the brand of hormonal contraceptive 68 . It appears that the effects of hormonal contraceptives observed in the general population are not apparent in athletes, however further research is required to assess this. In the case of body composition, it may be that athletes respond di erently to hormonal contraceptives, as athletes exercise more frequently and monitor their dietary intake more carefully 15 . In terms of muscle mass, the increased habitual exercise level and loading in athletes may provide a greater stimulus for muscle anabolism, which may di erentiate the two populations. ere may be complex interactions between direct and indirect e ects of hormonal contraceptive on the anabolic response of muscle to resistance exercise, however these e ects are currently unclear. e acute e ects of hormonal contraceptives are more apparent with the majority of studies observing no e ect on muscle strength or performance, despite reductions in VO 2max . We believe that additional studies on the e ects of progestin-only contraceptives on muscle strength and VO 2max are needed as this area has not been evaluated and newer formulations of OCs should be incorporated into research.
A summary of the effects of hormonal contraceptives on determinants of athletic performance.
P r o g e s t i n -o n l y contraceptives have been grouped together due to the paucity of r e s e a r c h o n t h e s e contraceptive delivery systems in athletes.
TABLE 2 -

Determinants of athletic performance
Combined oral contraceptives
Progestin-only contraceptives
Body composition
Con icting data showing combined oral contraceptive use both increased and reduced body mass and fat mass in athletes 16, 26 .
Several reports of negatives e ects in the general population although no studies have been conducted in athletes [19] [20] [21] [22] [23] [24] [25] .
Muscle mass accretion Combined oral contraceptive use may have a positive or negative e ect on strength gains depending upon the progestin used 16, [19] [20] [34] [35] .
Insu cient evidence, although the type of progestin-used may in uence the anabolic response of muscle to resistance exercise 20, 22 .
Muscle strength e majority of studies have reported no acute e ects of combined oral contraceptives on muscle strength [49] [50] [51] [52] .
Insu cient evidence to draw a conclusion.
Oxygen uptake
Combined oral contraceptive use may reduce VO 2max although this is less apparent in trained athletes [58] [59] [60] [61] [62] [63] [64] [65] .
Performance tests Combined oral contraceptives do not appear to acutely e ect exercise capacity or performance tests 26, 60, 62, [65] [66] .
It is also useful to note that few studies address the issue of sample size and power, with only a small number of studies with athletic participants reporting priori power analysis 52, 62, 64 . This issue makes it di cult to conclude either the statistical or clinical signi cance of many of the studies included in this overview, however it is clear that further research on the e ects of hormonal contraceptives is warranted and should not be con ned to oral contraceptives only. In particular, we propose that the e ects of long-acting, reversible, progestin-only contraceptives should be considered as their prevalence is increasing and these are likely to have different effects on performance than combined contraceptives.
This perspective also highlights the lack of information pertaining to the prevalence of hormonal contraceptive use in athletes. It would be bene cial to know the extent of hormonal contraceptive use in athletes so that future research can be directed appropriately. For example, in the general population the patch and ring are very rarely used: 0.1% use for patch and no recorded use of vaginal ring in 194,000 participants 9 , therefore if athletes show a similar trend for usage, it may not be justi ed to recommend research into their e ects in an athletic population. However, if athletes show an increased use of the patch or ring than the general population, then the composition of these contraceptives (exposure to ethinyl estradiol with the nuvaring is 3.4 times less than the contraceptive patch and 2.1 times less than OCs.
69 may indicate the need for more research. erefore, we strongly recommend that research into the prevalence of hormonal contraceptive use in athletes should be conducted.
Resumo
Uma perspectiva sobre a investigação dos efeitos dos contraceptivos hormonais sobre os fatores determinantes do desempenho de mulheres atletas Os métodos contraceptivos hormonais são usados por aproximadamente metade das atletas do sexo feminino e podem afetar o desempenho atlético como resultado de sua ação hormonal sistêmica. Nas atletas, o uso de anticoncepcionais parece ter pouco efeito sobre a composição corporal, porém novos estudos são necessários para avaliar os efeitos dos contraceptivos derivados apenas de progestina, pois podem ter um efeito negativo na população em geral. O tipo de progestina contido dentro do contraceptivo pode infl uenciar a resposta anabólica do músculo, embora esta relação seja complexa em virtude dos efeitos diretos ou indiretos de hormônios exógenos na síntese da proteína e na proliferação das células satélites. A resposta sistêmica hormonal alterada em usuárias de contraceptivos parece não infl uenciar a força muscular e, embora o consumo máximo de oxigênio às vezes seja reduzida, isso não afeta as medidas de desempenho. A maioria das pesquisas utilizou desenhos transversais e/ou agrupou diferentes tipos e marcas de anticoncepcionais hormonais e poucos estudos têm sido realizada sobre anticoncepcionais com progestina em atletas. Futuros estudos devem usar desenhos experimentais prospectivos, randomizados e controlados para avaliar os efeitos de todos os tipos de contraceptivos hormonais no desempenho atlético em mulheres.
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